Diversity Hemex Team
Meet Brandon García, our newest intern at HEMEX
New Year's resolutions can be a powerful way to make positive changes in life and [...]
Continue reading
Investment Press Release
Hera Biotech acquires Scailyte’s endometriosis diagnostic assets
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Clinical Development Innovation Investment Press Release
Resistell recruits first patients for international clinical study
Resistell recruits first patients for international clinical study
Continue reading
Innovation Investment Press Release
Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™ from the U.S. FDA
HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of [...]
Continue reading
Innovation Investment Press Release
Moving forward fast – ASPIVIX is finishing the 2022 with a new investment and a generous grant
We are thrilled to share that HEMEX is part of the investment consortium financing the [...]
Continue reading
Our portfolio company ARTIDIS announces today promising data from their first prospective study conducted at the Breast Center in Basel, Switzerland. The spin-off from the Biozentrum at the University of Basel has succesfully developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. HEMEX AG is a privately-owned Swiss investment and consulting company headquartered […]
The new GeoHealthApp enables users in Germany and Switzerland to determine their individual infection risk for COVID-19, thus making a pivotal contribution to reduce the spread of SARS-CoV2. Through a traffic light system on their smartphone display, users receive information about individualized current infection risks. The information results from the frequented locations of the past […]
- 1
- 2